Natera Inc (NASDAQ:NTRA) Insider Sells $7,842,500.00 in Stock

Share on StockTwits

Natera Inc (NASDAQ:NTRA) insider Jonathan Sheena sold 250,000 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $31.37, for a total value of $7,842,500.00. Following the completion of the transaction, the insider now owns 364,645 shares of the company’s stock, valued at approximately $11,438,913.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jonathan Sheena also recently made the following trade(s):

  • On Monday, June 24th, Jonathan Sheena sold 500 shares of Natera stock. The shares were sold at an average price of $25.19, for a total value of $12,595.00.
  • On Monday, June 10th, Jonathan Sheena sold 1,033 shares of Natera stock. The shares were sold at an average price of $24.79, for a total value of $25,608.07.

Shares of NASDAQ NTRA opened at $27.61 on Thursday. Natera Inc has a one year low of $11.08 and a one year high of $33.25. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -12.84 and a beta of 1.51. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73. The business’s 50-day simple moving average is $27.16.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.09. Natera had a negative return on equity of 409.49% and a negative net margin of 46.78%. The firm had revenue of $74.36 million during the quarter, compared to analyst estimates of $66.77 million. During the same period last year, the company posted ($0.62) EPS. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. On average, equities research analysts forecast that Natera Inc will post -2.1 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Natera by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 5,604,296 shares of the medical research company’s stock worth $154,567,000 after acquiring an additional 832,187 shares during the period. BlackRock Inc. boosted its position in Natera by 74.4% during the 2nd quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock worth $133,552,000 after acquiring an additional 2,065,977 shares during the period. Jennison Associates LLC boosted its position in Natera by 24.4% during the 2nd quarter. Jennison Associates LLC now owns 4,434,727 shares of the medical research company’s stock worth $122,310,000 after acquiring an additional 869,420 shares during the period. FMR LLC raised its stake in shares of Natera by 57.0% during the 4th quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock worth $54,568,000 after purchasing an additional 1,419,390 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Natera by 4,307.7% during the 2nd quarter. Invesco Ltd. now owns 2,041,857 shares of the medical research company’s stock worth $56,314,000 after purchasing an additional 1,995,532 shares in the last quarter. Hedge funds and other institutional investors own 83.52% of the company’s stock.

A number of equities analysts recently weighed in on the company. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Piper Jaffray Companies increased their price target on Natera from $28.00 to $32.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. BidaskClub upgraded Natera from a “hold” rating to a “buy” rating in a research report on Friday, August 9th. Craig Hallum increased their price target on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Canaccord Genuity increased their price target on Natera from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $32.29.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: What does RSI mean?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gateley Holdings PLC  to Distribute Dividend of GBX 5.40 on  October 16th
Gateley Holdings PLC to Distribute Dividend of GBX 5.40 on October 16th
Equiniti Group PLC Plans Dividend of GBX 1.95
Equiniti Group PLC Plans Dividend of GBX 1.95
Armada Hoffler Properties  & Nam Tai Property  Head-To-Head Review
Armada Hoffler Properties & Nam Tai Property Head-To-Head Review
Critical Comparison: Taro Pharmaceutical Industries  and Genmab A/S
Critical Comparison: Taro Pharmaceutical Industries and Genmab A/S
Critical Comparison: Jerash Holdings   versus Its Rivals
Critical Comparison: Jerash Holdings versus Its Rivals
Comparing Symantec  & Tyler Technologies
Comparing Symantec & Tyler Technologies


 
© 2006-2019 Zolmax.